Navigation Links
Liposuctioned Fat Can Be Used for Breast Augmentation
Date:10/26/2009

Method may be safe alternative to implants, researchers say

MONDAY, Oct. 26 (HealthDay News) -- Using liposuctioned fat for breast augmentation may be a viable alternative to implants for some women, according to a new study.

The use of fat injections for breast augmentation has been the subject of ongoing debate because of a lack of research and worries that the fat may calcify and obscure mammograms, be mistaken for cancer or be re-absorbed by the body.

The study included 50 women, aged 17 to 63, who had 55 fat-grafting procedures (five women were grafted twice) to their breasts with fat taken from their upper thighs and other areas. The patients were followed-up for between nine months and five years, with an average follow-up of three years.

The researchers found that the grafts didn't obscure mammography and that the women didn't have any suspicious breast masses, nodules or lesions that might interfere with cancer detection.

Among the other findings:

  • Graft survival averaged 85 percent.
  • The average increase in breast volume at six to 12 months was 210 milliliters.
  • The procedure can be performed in 90 minutes.

The study was scheduled for presentation at the annual meeting of the American Society of Plastic Surgeons, held Oct. 23 to 27 in Seattle.

Another study scheduled for presentation at the meeting found that injecting fat into the breasts gives breast-lift patients a new option for improving breast size and shape, with a reduced risk of some of the complications associated with breast implants.

Many women who have breast lifts require some amount of augmentation to fill out their breasts. Breast implants are typically used in these cases.

This study included 46 women who received fat injections to their breasts after a breast lift. The fat was taken from the thigh, abdomen or other areas on the patient's body. After one
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... People in Minnesota have a great option ... offering its 28 Day Fat Loss Formula. The best ... of their own home. The product sells for $135 dollars ... be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is ... now, but after using the 28 Day Fat Loss Formula ...
(Date:5/19/2013)... New York (PRWEB) May 19, 2013 ... in a federal litigation now underway in U.S. District ... Case Management Order dated May 3rd, the Court has ... Nominee Pool to eight cases rather than four. The ... scheduled for Thursday, May 23rd. (In re: Actos Product ...
(Date:5/19/2013)... City, Utah (PRWEB) May 19, 2013 ... information on small business health insurance . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... start-ups, and the self-employed intrinsically know the value ...
(Date:5/19/2013)... According to a new market research report ... 2018): By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), Surveillance, ... IS, Infrared, X-Ray) And Geography" published by MarketsandMarkets, ... billion in 2012 and is expected to reach ... of 3.84% from 2013 to 2018. In terms ...
(Date:5/19/2013)... 19, 2013 These molecular diagnostics ... UK, Spain, Japan, Italy, Germany and France:, ... diagnostics laboratory practice, as well as key economic, ... market impact during the next five years. , ... biochip technologies, test formats, detection methodologies, trends in ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4
... 31, 2008) Real-world use of a novel drug-eluting ... good clinical outcomes, according to one-year data from a ... focused on the sirolimus-eluting Excel stent, are being reported ... SCAI Annual Scientific Sessions in Partnership with ACC i2 ...
... 31, 2008) A large community-based registry of patients ... how long patients with complex coronary artery disease typically ... drug that prevents unwanted blood clots; why they stop ... decision. , The new data from the MATRIX ...
... Percutaneous coronary intervention (PCI) may be a reasonable ... the left main coronary artery, according to a study ... when stents and bypass surgery were used to restore ... were treated with stenting were more likely to need ...
... refined salt prompt consumers, food industry to consider ... benefits of natural sea ... chemicals over a dinner plate - yet that,s exactly what millions,of ... food,with refined table salt, says Mark Zoske, co-founder of SaltWorks, Inc.,( ...
... Teleconference Tuesday, April 1, 2008 at 9:30 AM EDT, ... Bulletin Board: MLSS), the recognized leader in,advanced injection technologies, ... fiscal year, ended December 31, 2007., Key ... System was formally unveiled to market at ...
... Pharmaceutical Holdings, Inc. (Amex: KUN ) ("China ... research, development, manufacture,and marketing of pharmaceutical, nutritional supplement ... ("PRC"), today announced it will,conduct a conference call ... 2008, to,discuss the Company,s financial results for the ...
Cached Medicine News:Health News:Registry unveils 'real-world' data on novel excel stent 2Health News:Matrix registry probes adherence to clopidogrel at 1 year 2Health News:Matrix registry probes adherence to clopidogrel at 1 year 3Health News:Study finds support for PCI in unprotected left main disease 2Health News:Study finds support for PCI in unprotected left main disease 3Health News:SaltWorks, Inc. Advises Table Salt Alternatives 2Health News:Milestone Scientific Announces 2007 Year-End Results 2Health News:Milestone Scientific Announces 2007 Year-End Results 3Health News:Milestone Scientific Announces 2007 Year-End Results 4Health News:Milestone Scientific Announces 2007 Year-End Results 5Health News:Milestone Scientific Announces 2007 Year-End Results 6Health News:Milestone Scientific Announces 2007 Year-End Results 7Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 3
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
(Date:5/16/2013)... 2013  Today, the National Patient Advocate Foundation acknowledges ... of Representatives recently approved a bill that would prohibit ... higher out-of-pocket fees for newer, more expensive oral anti-cancer ... more severe side-effects. However, the bill was amended to ... continue to be a barrier to patients with cancer ...
(Date:5/16/2013)... May 16, 2013  Amgen (NASDAQ: AMGN ) ... Tuesday, May 21, 2013, at the Sheraton New York Times ... at 10:00 a.m. Eastern Daylight Time. Joseph P. ... and Development at Amgen, will present at the conference. Live ... Calendar on Amgen,s website, www.amgen.com , under Investors. A ...
Breaking Medicine Technology:AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... LONDON , March 17, 2010 Hikma Pharmaceuticals,today announced 2009 preliminary results with operating profits up 36% on the,back of a strong performance from its Middle East ... , ... ... ...
... 16 American pharmaceutical manufacturer Alpharma Inc. has agreed ... Act allegations in connection with the marketing of the morphine-based ... allegations that, between January 1, 2000 and ... induce them to promote or prescribe Kadian, and made misrepresentations ...
Cached Medicine Technology:Hikma 2009 Results Interviews With CEO and CFO 2Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 2Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: